YUMAB GmbH, a privately-held German biotechnology company, and Merck, a leading science and technology company, have signed a research and collaboration agreement on July 22nd, 2019. Within the scope of this cooperation, Merck’s Healthcare business will complement its own drug discovery efforts by utilizing YUMAB’s expertise, its comprehensive antibody libraries and its established technology platform to generate novel therapeutic antibodies. YUMAB welcomes the opportunity to adjust its platform and technologies to the needs of a global pharmaceutical company. Financial conditions of the agreement were not disclosed.
Thomas Schirrmann, CEO of YUMAB, comments:“Since the early days of YUMAB, both companies have collaborated based on a shared commitment to accelerating drug discovery, and we look forward to our continuing collaborations enhanced by this new research effort.”